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Under PIO, insulin sensitivity improved, as assessed by increased total glucose
disposal rate (1.9870.24 for PIO versus 1.5870.12 umol/kg/min for PL,
po0.05), and reduced glucose endogenous hepatic production. PIO did not
affect post-dialysis bodyweight, total fat and lean body mass, but signiﬁcantly
reduced visceral adipose tissue (VAT) area and the VAT/SAT (subcutaneous
adipose tissue) ratio. HDL-cholesterol signiﬁcantly increased. PIO decreased
CRP (3.9671.44 mg/l vs 7.8872.56, po0.05), plasma leptin, and
dramatically reduced leptin/adiponectin ratio. Glycerol turnover, circulating
glycerol and non esteriﬁed fatty acids were paradoxically increased. In
conclusion, the improvement in insulin sensitivity by PIO, in non diabetic
dialyzed patients, was associated with favorable metabolic effects, reduction
in inﬂammation and body fat redistribution. The stimulation of systemic
lipolysis was a surprising ﬁnding which may reﬂect adipose tissue remodeling
and/or a paradoxical lypolitic effect of PIO in this population.
http://dx.doi.org/10.1016/j.krcp.2012.04.578
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QUANTIFICATION OF THE DIFFERENCE BETWEEN PRE-DIALYSIS AND
POST-DIALYSIS SERUM ALBUMIN MEASUREMENT AND ITS
RELATIONSHIP TO INTRA-DIALYTIC WEIGHT GAIN
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Haemodialysis patients may have low albumin levels due to a cascade of
factors, including inﬂammation and reduced dietary intake. Albumin is
commonly used in clinical settings by dieticians as part of a comprehensive
nutritional assessment. Presently many dietetic practitioners use
interchangeably pre-dialysis and post-dialysis biochemical measurements for
albumin. The aim of this study was to quantify the difference between pre-
dialysis and post-dialysis serum albumin measurement and its relationship to
intra-dialytic weight gain. Fourty-six stable (21 Australian indigenous, 25
non-indigenous) haemodialysis patients were enrolled in a three month
cross-sectional study. During the study patients underwent routine
haemodialysis treatment and biochemical tests. Weight and biochemical
measurements were collected pre and post dialysis on the ﬁrst Tuesday or
Wednesday of each month. A patient generated subjective global assessment
(PG-SGA) was conducted in the thirdmonth of the study. The incidence of low
albumin levels (o35g/L) was 56% (n¼26) when serum albumin was
measured pre-dialysis, this was reduced to 30% (n¼14) when measured post-
dialysis. Analysis of serum albumin found a 2.6g/L (CI 1.7-3.5) difference in
concentration between pre and post dialysis measurements (p¼0.000), with
serum albumin less concentrated in pre-dialysis blood samples. Intra-dialytic
weight gain (2.0kg, CI 1.7-2.3) correlated with the change in serum albumin
(r¼ 0.464, p¼0.001). Intra-dialytic weight gain and the difference between
pre and post dialysis serum albumin was greater in Australian indigenous
patients than in non-indigenous patients. PG-SGA score was more strongly
correlated with post-dialysis than pre-dialysis serum albumin (r¼0.430,
p¼0.003; r¼0.389, p¼0.008 respectively).This study indicates that
measurement of serum albumin should be undertaken post-dialysis when
using the measurement as part of a nutritional assessment. Pre-dialysis serum
albumin measurement may falsely indicate poor nutritional status, and
should be followed with a post-dialysis measurement to conﬁrm ﬁnding.
http://dx.doi.org/10.1016/j.krcp.2012.04.579
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Indigenous Australians have an increased incidence of kidney disease
and decreased survival on hemodialysis. The aim of this study was to
investigate whether differences in nutritional status exist between
indigenous and non-indigenous patients undergoing maintenance
hemodialysis in South Australia.
Seventy-two (22 Australian indigenous, 50 non-indigenous) stable
hemodialysis patients were enrolled in a three month cross-sectional
study. During the study patients underwent routine hemodialysis
treatment and biochemical tests. Weight and biochemical measurements
were collected pre and post dialysis on the ﬁrst Tuesday or Wednesday of
each month. A patient generated subjective global assessment (PG-SGA)
was conducted in the third month of the study.
Pre-dialysis albumin was 32.8þ/4.1g/L in Australian indigenous patients and
36.2þ/-4.5g/L in non-indigenous patients (p¼ 0.003). The difference between
pre-dialysis and post-dialysis albumin was -4.0þ/-2.8g/L in indigenous patients
and -1.0þ/-1.9g/L in non-indigenous patients (p¼0.000). Intra-dialytic weight
gain was 3.0þ/-2.6kg in indigenous patients and 2.0þ/-0.8kg in non-
indigenous patients (p¼0.010). Serum sodium and bicarbonate were 136.2þ/-
2.7mmol/L and 22.3þ/-1.7mmol/L in indigenous patients and 138.5þ/-
2.3mmol/L and 25.2þ/-5.8mmol/L in non-indigenous patients
(p¼0.010,0.003). Glucose, HbA1c and triglyceride were 9.7þ/-4.6mmol/L,
7.0þ/-1.7% and 2.2þ/-1.3mmol/L in indigenous patients and 7.0þ/-2.8mmol/L,
6.2þ/-1.0% and 1.4þ/-0.7mmol/L in non-indigenous patients (p¼ 0.005, 0.047,
0.016). No differences were observed in dry weight, PG-SGA, post-dialysis
albumin, serum potassium, urea, creatinine, parathyroid hormone, phosphate,
calcium, C-reactive protein or hemoglobin.
This study indicates that differences exist between Australian indigenous and
non-indigenous maintenance hemodialysis patients, with indigenous patients
less likely to be meeting recommendations.
http://dx.doi.org/10.1016/j.krcp.2012.04.580
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GUANIDINOACETIC ACID(GAA) IN PATIENTS WITH CHRONIC KIDNEY
DISEASE(CKD) AND DIABETES MELLITUS(DM)
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GAA is the precursor of creatine, an essential in the energy metabolism of
muscle and nerve tissue. GAA is mainly produced in the kidney. GAA
production was reported to be suppressed in the streptozotocin-induced
DM rats. However, GAA metabolism has not been really investigated in
CKD or DM patients. In this study, we determined serum level(S) and
urinary excretion(U) of GAA and creatinine(Cr) in patients with chronic
glomerulonephritis (CGN) and DM. The subjects were 15 healthy adults, 92
patients with CGN and 27 patients with non insulin-dependent DM
nephropathy. S and U-GAA were determined with HPLC. As shown in the
Table describing mean values, U-GAA of early stage CKD patients was
signiﬁcantly lower than healthy subject. And S-GAA decreased with loss of
renal function or with U-Cr, especially in DM patients.
N S-Cr U-Cr S-GAA U-GAA
(mg/dL) (mg/day) (mg/dL) (mg/day)
Normal 15 0.9 1633 38.2 103.0
CGN(Ccr490mL/min) 12 1 1742 41.1 41.3n
CGN(Ccro90mL/min) 24 1.5n 1385n 37.7 39.2n
CGN(Ccro30mL/min) 56 7.1n 715n 24.4n 5.9n
DM(Ccr460mL/min) 16 0.9 775n 27.8n 46.2n
DM(Ccro60mL/min) 11 5.0n 581n 22.1n 2.3n
In conclusion, GAA production in the kidney decreased in CKD patients,
suggesting GAA deﬁciency was a reason of muscle wasting of CKD and DM
patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.581
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EFFECTS OF GUANIDINOACETIC ACID(GAA) SUPPLEMENTATION IN RATS
WITH CHRONIC RENAL FAILURE(CRF)
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Osaka General Medical Center, Osaka, Japan
GAA is the precursor of creatine(CRT), an essential in the energy
metabolism of muscle and nerve tissue. GAA is mainly produced in the
kidney. We reported the GAA deﬁciency in CRF patients. This study was
designed to assess the effects of GAA supplementation(10 mg,100 mg/day
orally for 4 weeks respectively) for the muscle capabilities in CRF rats
prepared by 5/6 nephrectomy. Muscle power was assessed by the sliding
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